Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

Our understanding of tumor-infiltrating lymphocytes (TILs) is rapidly expanding beyond T cell-
centric perspectives to include B cells and plasma cells, collectively referred to as TIL-Bs. In …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

There is abundant evidence that tumor-infiltrating CD8+ T cells contribute positively to
antitumor immunity; however, the role of tumor-infiltrating B cells (TIL-B) and plasma cells …

B cells play essential roles in immunity, mainly through the production of high affinity plasma
cells (PCs) and memory B (Bmem) cells. The affinity maturation and differentiation of B cells …

Tumor-infiltrating lymphocytes (TILs), frontline soldiers of the adaptive immune system, are
recruited into the tumor site to fight against tumors. However, their small number and …

Tumor-infiltrating B cells (TIL-B) in breast cancer (BC) have previously been associated with
improved clinical outcomes; however, their roles in tumor immunity are not currently well …

Effective immunotherapy options for patients with non–small cell lung cancer (NSCLC) are
becoming increasingly available. The immunotherapy focus has been on tumor-infiltrating T …

The rationale behind cancer immunotherapy is based on the unequivocal demonstration
that the immune system plays an important role in limiting cancer initiation and progression …

The field of systemic cancer therapy for metastatic disease has entered an exciting era with
the advent of novel immunomodulatory strategies targeting immune checkpoints. At the …